1.Infliximab Partially Alleviates the Bite Force Reduction in a Mouse Model of Temporomandibular Joint Pain.
Sang Hyon KIM ; Chang Nam SON ; Hyo Jung LEE ; Ho Chan CHO ; Sung Won JUNG ; Ji An HUR ; Won Ki BAEK ; Hye Ra JUNG ; Ji Hee HONG
Journal of Korean Medical Science 2015;30(5):552-558
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.
Animals
;
Antirheumatic Agents/*therapeutic use
;
*Bite Force
;
Disease Models, Animal
;
Freund's Adjuvant/toxicity
;
Infliximab/*therapeutic use
;
Male
;
Mice
;
Mice, Inbred ICR
;
Temporomandibular Joint/pathology
;
Temporomandibular Joint Disorders/chemically induced/*drug therapy/pathology
;
Time Factors
2.Chemokine Receptor CXCR3 in the Spinal Cord Contributes to Chronic Itch in Mice.
Peng-Bo JING ; De-Li CAO ; Si-Si LI ; Meixuan ZHU ; Xue-Qiang BAI ; Xiao-Bo WU ; Yong-Jing GAO
Neuroscience Bulletin 2018;34(1):54-63
Recent studies have shown that the chemokine receptor CXCR3 and its ligand CXCL10 in the dorsal root ganglion mediate itch in experimental allergic contact dermatitis (ACD). CXCR3 in the spinal cord also contributes to the maintenance of neuropathic pain. However, whether spinal CXCR3 is involved in acute or chronic itch remains unclear. Here, we report that Cxcr3 mice showed normal scratching in acute itch models but reduced scratching in chronic itch models of dry skin and ACD. In contrast, both formalin-induced acute pain and complete Freund's adjuvant-induced chronic inflammatory pain were reduced in Cxcr3 mice. In addition, the expression of CXCR3 and CXCL10 was increased in the spinal cord in the dry skin model induced by acetone and diethyl ether followed by water (AEW). Intrathecal injection of a CXCR3 antagonist alleviated AEW-induced itch. Furthermore, touch-elicited itch (alloknesis) after compound 48/80 or AEW treatment was suppressed in Cxcr3 mice. Finally, AEW-induced astrocyte activation was inhibited in Cxcr3 mice. Taken together, these data suggest that spinal CXCR3 mediates chronic itch and alloknesis, and targeting CXCR3 may provide effective treatment for chronic pruritus.
Acetamides
;
therapeutic use
;
Animals
;
Chemokine CXCL10
;
metabolism
;
Chloroquine
;
toxicity
;
Chronic Disease
;
Cyclopropanes
;
adverse effects
;
Dehydration
;
complications
;
Dinitrofluorobenzene
;
adverse effects
;
Disease Models, Animal
;
Formaldehyde
;
toxicity
;
Freund's Adjuvant
;
toxicity
;
Mice
;
Mice, Inbred C57BL
;
Mice, Knockout
;
Motor Activity
;
drug effects
;
Pain
;
chemically induced
;
Pruritus
;
chemically induced
;
pathology
;
Pyrimidines
;
therapeutic use
;
Receptors, CXCR3
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Skin
;
pathology
;
Spinal Cord
;
drug effects
;
metabolism
;
pathology
;
Time Factors
;
p-Methoxy-N-methylphenethylamine
;
toxicity
3.Spinal CCL2 Promotes Central Sensitization, Long-Term Potentiation, and Inflammatory Pain via CCR2: Further Insights into Molecular, Synaptic, and Cellular Mechanisms.
Rou-Gang XIE ; Yong-Jing GAO ; Chul-Kyu PARK ; Ning LU ; Ceng LUO ; Wen-Ting WANG ; Sheng-Xi WU ; Ru-Rong JI
Neuroscience Bulletin 2018;34(1):13-21
Mounting evidence supports an important role of chemokines, produced by spinal cord astrocytes, in promoting central sensitization and chronic pain. In particular, CCL2 (C-C motif chemokine ligand 2) has been shown to enhance N-methyl-D-aspartate (NMDA)-induced currents in spinal outer lamina II (IIo) neurons. However, the exact molecular, synaptic, and cellular mechanisms by which CCL2 modulates central sensitization are still unclear. We found that spinal injection of the CCR2 antagonist RS504393 attenuated CCL2- and inflammation-induced hyperalgesia. Single-cell RT-PCR revealed CCR2 expression in excitatory vesicular glutamate transporter subtype 2-positive (VGLUT2) neurons. CCL2 increased NMDA-induced currents in CCR2/VGLUT2 neurons in lamina IIo; it also enhanced the synaptic NMDA currents evoked by dorsal root stimulation; and furthermore, it increased the total and synaptic NMDA currents in somatostatin-expressing excitatory neurons. Finally, intrathecal RS504393 reversed the long-term potentiation evoked in the spinal cord by C-fiber stimulation. Our findings suggest that CCL2 directly modulates synaptic plasticity in CCR2-expressing excitatory neurons in spinal lamina IIo, and this underlies the generation of central sensitization in pathological pain.
Animals
;
Benzoxazines
;
pharmacology
;
therapeutic use
;
Chemokine CCL2
;
antagonists & inhibitors
;
genetics
;
metabolism
;
pharmacology
;
Excitatory Amino Acid Agents
;
pharmacology
;
Excitatory Amino Acid Agonists
;
pharmacology
;
Female
;
Freund's Adjuvant
;
toxicity
;
Hyperalgesia
;
chemically induced
;
metabolism
;
prevention & control
;
Long-Term Potentiation
;
drug effects
;
physiology
;
Luminescent Proteins
;
genetics
;
metabolism
;
Male
;
Mice
;
Mice, Inbred C57BL
;
Mice, Transgenic
;
Myelitis
;
chemically induced
;
drug therapy
;
metabolism
;
Neurons
;
drug effects
;
Pain Management
;
Somatostatin
;
genetics
;
metabolism
;
Spinal Cord
;
cytology
;
Spiro Compounds
;
pharmacology
;
therapeutic use
;
Vesicular Glutamate Transport Protein 2
;
genetics
;
metabolism
;
Vesicular Inhibitory Amino Acid Transport Proteins
;
genetics
;
metabolism